NIO Launches ONVO L90, a Family-Centric Electric SUV With 605 KM Range
Warning! GuruFocus has detected 4 Warning Signs with NIO.
China will receive deliveries on August 1. The SUV has a 900V basis and a family-friendly cabin. L90 has a 5,145-mm length and 3,110-mm wheelbase. The cabin is 4,195 mm long and includes 670 liters of rear and 240 liters of front storage. The most space in a Chinese electric vehicle.
Normal 85 kWh batteries can take the automobile 605 kilometers. The two-wheel-drive model uses 14.5 kWh/100 km. The all-wheel-drive model has 440 kW and reaches 100 km/h in 4.7 seconds.
NIO has 3,400 battery swaps and 4,659 recharge stations in 550 Chinese sites. The L90 leverages this network to help long-distance travelers with range issues.
The body is 84% aluminum alloy and ultra-high-strength steel, with nine airbags and a 2.92-meter side curtain airbag system. The 2024 C-NCAP and C-IASI five-star safety standards were met by the L90.
Inside, customers can choose six or seven seats and three themes. Also included are ambient lights and titanium accents. The L90 has the NT.Coconut 2.0 ONVO Smart System. It manages the smart interior, car controls, and driving.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Little-known road rule benefiting EV drivers prompts reminder to Aussies
Australians are being reminded of a little-known road rule specifically benefiting electric vehicle drivers. Online this week, Aussies in a community group shared that in the ACT and NSW, EVs are allowed to drive in the transit lanes, regardless of how many occupants are in the car. This is at odds with typical rules that state there must be two or sometimes three people in the car, and many responding said they didn't know about the transit lane exemption. "Never knew about it," one person said. "I had no idea," commented another. Transit lanes — marked as T2 or T3 — are designed to reduce congestion and encourage more efficient travel by prioritising vehicles carrying multiple people. T2 lanes require at least two occupants, while T3 lanes require three or more. They operate during peak hours or as signed, and vehicles such as buses, taxis, motorcycles and bicycles can use them freely regardless of passenger numbers. Drivers not meeting the minimum occupant requirement can only enter transit lanes briefly, typically up to 100 metres, to overtake or turn. But in NSW and the ACT, EVs with a blue EV label on their number plates are allowed to use T2 and T3 lanes even when carrying only the driver. This exemption forms part of a government effort to encourage EV uptake by offering practical incentives. It was introduced in 2022 and was recently extended until June 30, 2027, in NSW. Other states like Queensland and Victoria do not offer similar allowances. Little-known road rule with $600 fine shocks Aussies Drivers warned major road rule change with $961 fines 'just weeks' away Common road act that carries a fine in every Aussie state Why do we have transit lanes? The point of transit lanes is to reduce traffic congestion and improve the efficiency of road networks, particularly during peak travel times. By giving priority to vehicles carrying multiple passengers, such as carpoolers, buses, taxis, and motorcycles, transit lanes aim to: Encourage ride-sharing and reduce the number of single-occupant vehicles on the road Speed up travel times for high-occupancy vehicles and public transport Lower overall emissions by cutting the number of cars on the road Do you have a story tip? Email: newsroomau@ You can also follow us on Facebook, Instagram, TikTok, Twitter and YouTube.
Yahoo
2 hours ago
- Yahoo
Hyundai Builds N Charging Station At Nürburgring To Support Performance EVs
Hyundai Builds N Charging Station At Nürburgring To Support Performance EVs originally appeared on Autoblog. Hyundai's high-performance N division is going all-in on electric speed, and now it has the hardware to match. Fresh off a successful Ioniq 6 N debut at Goodwood, the company has confirmed it will open a new N-branded fast-charging station right at the Nürburgring — one of the most fearsome test tracks on Earth and the spiritual home of the N not just for PR, either. The facility is open to the public, supports rapid charging for any compatible EV, and further signals Hyundai's long-term belief that performance driving and electrification can go hand-in-hand — even in the Green Concept To Charging Cables The Nürburgring station is Hyundai's second N Charging Station globally, following the first one launched last year in Australia. Positioned beside the Nordschleife circuit entrance, the new unit will deliver 150 kW fast charging, allowing drivers to juice up quickly between laps — whether they drive a Hyundai or part of Hyundai's broader transformation into a mainstream EV powerhouse, a journey that's been years in the making. Over the last 50 years, the company has evolved from humble beginnings with the Hyundai Excel to premium offerings like the G90 and radical design shifts that redefined its lineup entirely. What was once a budget badge is now a legitimate force in both electrification and performance . Heritage Meets High Voltage There's symbolism here too. Nürburgring isn't just any track — it's where the N philosophy was born. Hyundai N cars are developed, tortured, and refined on this 13-mile stretch of twisting asphalt. That's why it matters that this is more than just a marketing stunt. With the Ioniq 5 N and now the Ioniq 6 N entering production, Hyundai's electrified N cars aren't concept dreams. They're production comes at a pivotal time. Q2 profits were slightly down, with the company's operating margin slipping nearly 16% amid rising global tariffs. But thanks to surging U.S. sales and record hybrid demand, Hyundai still pulled in roughly $35.3 billion in quarterly revenue, managing to beat analyst expectations by a whisker. Performance For Everyone The N Charging Station is also a nod to Hyundai's inclusive approach. Unlike some brands fencing off their fast chargers for proprietary use, Hyundai is embracing open access. Whether you're lapping the Ring in an Ioniq or daily-driving a rival EV, if your car supports fast charging, you're another reminder that while other automakers chase exclusivity, Hyundai's betting on accessibility, affordability, and performance. Much like its strategy in the U.S. — where the brand sells more cars than ever without even fielding a full EV lineup — the Korean giant continues to prove you don't need to be the flashiest brand in the room to make a lasting impact. Looking Back, Driving Forward This moment is the latest step in a long line of efforts by Hyundai to embed itself into performance culture. Long before the Ioniqs, long before 'N' meant Nürburgring, Hyundai's earlier models helped define its global rise. From unsung 1980s sedans to quirky niche crossovers, the brand has always punched above its weight, often in overlooked with the Nürburgring charger live and its electric N cars in showrooms, Hyundai has tied past and future together with a charging cable. Hyundai Builds N Charging Station At Nürburgring To Support Performance EVs first appeared on Autoblog on Jul 26, 2025 This story was originally reported by Autoblog on Jul 26, 2025, where it first appeared.
Yahoo
3 hours ago
- Yahoo
Pharma sector outlook as Trump's drug tariff deadline looms
Pharmaceutical stocks are in focus as President Trump's drug tariff deadline looms. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination with Josh Lipton to discuss the impact that pharmaceutical tariffs could have on the sector, Astrazeneca's (AZN) $50 billion commitment to US investments, and how the industry is navigating pressure from Washington and shifting global demand. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. Pharmaceutical stocks in focus as we approach President Trump's looming drug tariff deadline. For more, I want to bring in Yahoo Finance senior health reporter Angelique Chenge. That's right, Josh. With that looming deadline, potentially August 1st, for up to 200% in tariffs, we don't know what that number will actually end up being. We've heard from several companies that have announced manufacturing commitments in hopes to thwart that effort. That includes AstraZeneca. We spoke to CEO Pascal Soriot about that, and he did mention that the announcement for $50 billion, that's in addition to $3.5 billion last year, is in part a response to Trump's tariffs. We know others like Eli Lilly and Johnson & Johnson have also announced similarly big announcements of commitments for manufacturing. And this is in play at a time where the industry is also going through a bit of tumult. We know that there is a lot of investment in one of Trump's least favorite countries, that is China. That is the reason why there has been a lot of tension in the biotech world. We also know that big pharma has been pivoting and investing there as well. Licensing deals and the like are on the rise as they look to sort of respond to all the different countries that are looking for what has now been termed health sovereignty. And this plays into that. So, when I asked Pascal about that, about China and the deal making there, here's what he had to say about it. We believe that it's our ethical responsibility to bring medicines to as many people as possible. Of course, there are limitations to what we can do, but we work very hard to do this. And we are lucky enough or good enough or both, that we are growing. And growth brings opportunities. And because we are growing, we are able to invest in United States for the United States, we're able to invest in China for China, and we're also able to seek innovation where it happens. Because actually, if innovation happens in China or in Europe, we need to take this innovation, develop it, and bring it to patients for instance in the United States, but manufacture the product in the United States. Um, and I think that brings me to an important point that people don't talk enough about is that today innovation in our industry takes place in the U.S. U.S. is the biggest innovator for biopharmaceuticals. And it's really important that everything is done to protect that innovation. It's a fantastic engine to bring new medicines to patients but also create good jobs, well-paid jobs, and economic growth. So, as you can hear, a lot of focus on that, on economic growth being the driver as well and needing to respond to these countries and their efforts. AstraZeneca also talked about how it would help shift revenues for the portfolio with a greater reliance on the U.S. Currently, 42% of revenues comes from the U.S. And with this increase in manufacturing, it would be 50%. And that includes GLP-1s. We know that there's a lot of global demand for that drug and for those types of drugs. AstraZeneca has been pursuing an oral form or pill form, which is largely seen as the next frontier in this space. AstraZeneca looking at being able to then supply the rest of the world from the U.S., making it a larger exporter. So, here's what Pascal said about that. It's also a reason, another reason why we are investing in this very large facility. We have our oral GLP-1. Everybody knows GLP-1 by now. These are agents used to help people manage their weight. We have an oral agent, and we have bet on oral agents because we think they are going to be easier for patients, because they will be cheaper, they'll be more accessible, and we will be able to export them around the world, not only supply America. But we also have other products treating cardiovascular metabolic disease. We have a new agent for hypertension for patients who are not controlled on multi-medicines. We have an oral PCSK9 for the control of cholesterol and many others. Cardiovascular metabolic diseases are the biggest killer in the world today, including in the United States. So, you can see the needs are enormous. This plant will supply products for American patients, so American patients will access products that are American-made. But this plant will also export to the billions of patients around the world who need these medicines. The company really moving that pot of money, you know, globally and looking at where it makes the most sense. Pascal also did tell me that in looking at the different areas of the world where the money can be, you know, invested, China, of course, being one of them. And then if you compare the amount that has been put in there, that is $5.3 billion is one of the latest deals that AstraZeneca has done in China. And if you compare that to the $50 billion, while not on the same level, you can still see it's quite a large number. And that's just one of those deals. So, we're starting to see a little bit of bifurcation in how the global pharmaceutical economy is functioning. Related Videos Uncertainty is 'here to stay': What that means for markets BlackRock's Rick Rieder: I Think Rates Can Come Down Elon Musk's 'master plan': Is Tesla an EV maker or AI play? 'We ask for more data' than FICO: VantageScore CEO Sign in to access your portfolio
